Abstract:The prevalence of kidney disease is increasing rapidly worldwide, reflecting rising rates of obesity, diabetes, and associated metabolic syndrome (MetS). Chronic kidney disease and related comorbidities such as obesity, diabetes, and hypertension place a significant financial burden on healthcare systems. Despite the widespread use of RAAS inhibitors, intensive blood pressure and glycemic control, and newer therapeutic options consisting of sodium/glucose cotransporter-2 (SGLT-2) inhibitors or glucagon-like peptide-1 (GLP-1) receptor agonists, a significant risk of progression to end-stage renal disease remains in the high-risk obese and diabetic population. The MetS is a cluster of cardiovascular risk factors that adversely affect the development and progression of chronic kidney failure. According to the criteria of the World Health Organization, it is defined by visceral adiposity, impaired glucose tolerance or insulin resistance, atherogenic dyslipidemia, raised blood pressure, and microalbuminuria with a albumin-to-creatinine ratio ≥30 mg/g. At molecular level MetS is marked by a proinflammatory state and increased oxidative stress leading to various pathophysiological changes causing endothelial dysfunction and a hypercoagulable state. Because the kidney is a highly vascularized organ, it is especially susceptible for those microvascular changes. Therefore, the MetS and its individual components are associated with the premature development, acceleration, and progression of chronic kidney disease. Therefore, it is becoming increasingly important to elucidate the underlying mechanisms of MetS-associated chronic kidney disease in order to develop new strategies for preventing and slowing the progression of renal disease. In this review, we will elucidate (i) the renal structural, hemodynamic, and metabolic changes that occur in obesity and obesity-related kidney injury; (ii) the clinicopathological characteristics of obesity-related kidney injury, primarily focusing on obesity-associated glomerulopathy; (iii) the potential additional factors or predisposing factors that may turn patients more susceptible to renal structural or functional compensatory failure and subsequent injury.

Metabolic Syndrome, Kidney-Related Adiposity, and Kidney Microcirculation: Unraveling the Damage

Metabolic Syndrome-Related Kidney Injury: A Review and Update

Association of metabolic syndrome and chronic kidney disease

Increased Glomerular Filtration Rate in Early Metabolic Syndrome is Associated with Renal Adiposity and Microvascular Proliferation.

The Metabolic Syndrome and Chronic Kidney Disease in U.S. Adults

Metabolic syndrome as a risk factor for the development of kidney dysfunction: a meta-analysis of observational cohort studies

Coordinated Contribution of NADPH Oxidase- and Mitochondria-Derived Reactive Oxygen Species in Metabolic Syndrome and Its Implication in Renal Dysfunction

Possible Link between Metabolic Syndrome and Chronic Kidney Disease in the Development of Cardiovascular Disease

Chronic kidney disease combined with metabolic syndrome is a non-negligible risk factor

Relationship between Metabolic Syndrome and Chronic Kidney Disease

The Effect of Metabolic Syndrome and Its Individual Components on Renal Function: A Meta-Analysis

From Adipose to Ailing Kidneys: The Role of Lipid Metabolism in Obesity-Related Chronic Kidney Disease

Lipid metabolism and renal disease.

Cardiovascular consequences of metabolic syndrome

Superimposition of Metabolic Syndrome Magnifies Post-Stenotic Kidney Injury in Dyslipidemic Pigs.

Obesity-Metabolic Derangement Preserves Hemodynamics but Promotes Intrarenal Adiposity and Macrophage Infiltration in Swine Renovascular Disease

Metabolic Syndrome and Its Components Associated with Endothelial Dysfunction in Chronic Kidney Disease Patients

Systemic and Cardiac Microvascular Dysfunction in Hypertension

Exploring metabolic dysfunction in chronic kidney disease

Microvascular perfusion heterogeneity contributes to peripheral vascular disease in metabolic syndrome

A Synopsis of the Evidence for the Science and Clinical Management of Cardiovascular-Kidney-Metabolic (CKM) Syndrome: A Scientific Statement From the American Heart Association